Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Arterial Ageing

  • Lee, Seung-Jun (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Park, Sung-Ha (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine)
  • Published : 2013.02.28
⟨ Previous Next ⟩

Abstract

Arterial ageing is characterized by age associated degeneration and sclerosis of the media layer of the large arteries. However, besides ageing, clinical conditions, which enhance oxidative stress and inflammation act to accelerate the degree of arterial ageing. In this review, we summarized the pathophysiology and contributing factors that accelerate arterial ageing. Among them, we focused on hypertension, the renin-angiotensin-aldosterone system and vascular inflammation which are modifiable causes of the arterial ageing process. Also, novel treatment targets derived from the disease models such as the Hutchinson Gilford Progeria Syndrome were reviewed.

Keywords

References

  1. Damjanov I, Linder J. Anderson's Pathology. 10th ed. St. Louis, MO: Mosby;1996.
  2. Kumar V, Abbas A, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005.
  3. Fishbein GA, Fishbein MC. Arteriosclerosis: rethinking the current classification. Arch Pathol Lab Med 2009;133:1309-16.
  4. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatr Gerontol Int 2010;10 Suppl 1:S213-20. https://doi.org/10.1111/j.1447-0594.2010.00603.x
  5. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104: 503-16. https://doi.org/10.1016/S0092-8674(01)00238-0
  6. Li Z, Froehlich J, Galis ZS, Lakatta EG. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999;33:116-23. https://doi.org/10.1161/01.HYP.33.1.116
  7. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991;88:904-10. https://doi.org/10.1172/JCI115393
  8. Huynh J, Nishimura N, Rana K, et al. Age-related intimal stiffening enhances endothelial permeability and leukocyte transmigration. Sci Transl Med 2011;3:112ra122.
  9. Yildiz O. Vascular smooth muscle and endothelial functions in aging. Ann N Y Acad Sci 2007;1100:353-60. https://doi.org/10.1196/annals.1395.038
  10. Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993;88:77-81. https://doi.org/10.1161/01.CIR.88.1.77
  11. Tsujimoto G, Lee CH, Hoffman BB. Age-related decrease in beta adrenergic receptor-mediated vascular smooth muscle relaxation. J Pharmacol Exp Ther 1986;239:411-5.
  12. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010;121: 505-11. https://doi.org/10.1161/CIRCULATIONAHA.109.886655
  13. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41. https://doi.org/10.1161/01.HYP.37.5.1236
  14. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
  15. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. https://doi.org/10.1097/HJH.0b013e3281fc975a
  16. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202-7. https://doi.org/10.1161/hc1002.105135
  17. Masugata H, Senda S, Murao K, et al. Association between urinary 8-hydroxydeoxyguanosine, an indicator of oxidative stress, and the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb 2012;19:747-55.
  18. Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J 2012;53:258-61. https://doi.org/10.3349/ymj.2012.53.2.258
  19. van Bussel BC, Schouten F, Henry RM, et al. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011;58:588-95. https://doi.org/10.1161/HYPERTENSIONAHA.111.174557
  20. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004;5:102-8. https://doi.org/10.3317/jraas.2004.025
  21. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation 2001;103:987-92. https://doi.org/10.1161/01.CIR.103.7.987
  22. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003;26:609-14. https://doi.org/10.1291/hypres.26.609
  23. Munakata M, Nagasaki A, Nunokawa T, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004;17(11 Pt 1):1050-5. https://doi.org/10.1016/j.amjhyper.2004.06.028
  24. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92. https://doi.org/10.1111/j.1476-5381.2010.00750.x
  25. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012; 221:18-33. https://doi.org/10.1016/j.atherosclerosis.2011.12.005
  26. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24:983-91. https://doi.org/10.1097/01.hjh.0000226182.60321.69
  27. Patarroyo Aponte MM, Francis GS. Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention. Curr Cardiol Rep 2012;14:433-42. https://doi.org/10.1007/s11886-012-0275-9
  28. Park S, Kim JB, Shim CY, et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007;25:1279-83. https://doi.org/10.1097/HJH.0b013e3280f31b6e
  29. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in earlystage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009;54:505-12. https://doi.org/10.1016/j.jacc.2009.03.066
  30. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002;106:2848-53. https://doi.org/10.1161/01.CIR.0000039328.33137.6C
  31. Nehme JA, Lacolley P, Labat C, et al. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol 2005;39:511-9. https://doi.org/10.1016/j.yjmcc.2005.05.015
  32. Wang M, Zhang J, Jiang LQ, et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 2007;50:219-27. https://doi.org/10.1161/HYPERTENSIONAHA.107.089409
  33. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90: 251-62.
  34. Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004;94: 1203-10. https://doi.org/10.1161/01.RES.0000126924.23467.A3
  35. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein- 1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992;148:2423-8.
  36. Guo F, Liu J, Wang C, Liu N, Lu P. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: proinflammatory effect on atherosclerosis. Biochem Biophys Res Commun 2009;390:942-6. https://doi.org/10.1016/j.bbrc.2009.10.082
  37. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16 Suppl A:11-4; discussion 14-5.
  38. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 2006;6:227-31. https://doi.org/10.2174/187152906779010719
  39. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004;176:111-6. https://doi.org/10.1016/j.atherosclerosis.2004.04.014
  40. Rodriguez-Manas L, El-Assar M, Vallejo S, et al. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 2009;8:226-38. https://doi.org/10.1111/j.1474-9726.2009.00466.x
  41. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein- mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531-4. https://doi.org/10.1161/01.CIR.103.21.2531
  42. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005;46:1118-22. https://doi.org/10.1161/01.HYP.0000185463.27209.b0
  43. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005;180:189-95. https://doi.org/10.1016/j.atherosclerosis.2004.11.019
  44. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403. https://doi.org/10.1161/01.HYP.38.3.399
  45. Provan SA, Angel K, Semb AG, et al. Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. J Rheumatol 2011; 38:606-12. https://doi.org/10.3899/jrheum.100689
  46. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92. https://doi.org/10.1161/CIRCULATIONAHA.105.601641
  47. Yildiz M, Yildiz BS, Soy M, Tutkan H. Impairment of arterial distensibility in premenopausal women with systemic lupus erythematosus. Kardiol Pol 2008;66:1194-9; discussion 1200-1.
  48. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1418-23. https://doi.org/10.1093/rheumatology/kep251
  49. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation 2011;123:1650-60. https://doi.org/10.1161/CIRCULATIONAHA.110.007021
  50. Reunert J, Wentzell R, Walter M, et al. Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn. Eur J Hum Genet 2012;20:933-7. https://doi.org/10.1038/ejhg.2012.36
  51. Ragnauth CD, Warren DT, Liu Y, et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010;121:2200-10. https://doi.org/10.1161/CIRCULATIONAHA.109.902056
  52. Lefevre C, Auclair M, Boccara F, et al. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010;30:2611-20. https://doi.org/10.1161/ATVBAHA.110.213603
  53. Capell BC, Olive M, Erdos MR, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A 2008;105: 15902-7. https://doi.org/10.1073/pnas.0807840105
  54. Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005;14: 2959-69. https://doi.org/10.1093/hmg/ddi326
  55. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2005;102:14416-21. https://doi.org/10.1073/pnas.0503712102
  56. Mans RA, McMahon LL, Li L. Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience 2012;202:1-9. https://doi.org/10.1016/j.neuroscience.2011.12.007
  57. Hongo M, Kumazaki S, Izawa A, et al. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J 2011;75:2660-7. https://doi.org/10.1253/circj.CJ-11-0497
  58. Cenni V, Capanni C, Columbaro M, et al. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. Eur J Histochem 2011;55:e36. https://doi.org/10.4081/ejh.2011.e36

Cited by

  1. Influence of training status and eNOS haplotypes on plasma nitrite concentrations in normotensive older adults: a hypothesis-generating study vol.26, pp.6, 2014, https://doi.org/10.1007/s40520-014-0218-y
  2. Photoplethysmographic signal waveform index for detection of increased arterial stiffness vol.35, pp.10, 2013, https://doi.org/10.1088/0967-3334/35/10/2027
  3. The Protective Effect of Lipoic Acid on Selected Cardiovascular Diseases Caused by Age-Related Oxidative Stress vol.2015, pp.None, 2013, https://doi.org/10.1155/2015/313021
  4. Are Gujarati Asian Indians 'older' for their 'vascular age' as compared to their 'Chronological age'? vol.108, pp.2, 2013, https://doi.org/10.1093/qjmed/hcu158
  5. Lack of association between arterial stiffness and genetic variants by genome-wide association scan vol.24, pp.4, 2013, https://doi.org/10.3109/08037051.2015.1049430
  6. Black Raspberry Extract Increased Circulating Endothelial Progenitor Cells and Improved Arterial Stiffness in Patients with Metabolic Syndrome: A Randomized Controlled Trial vol.19, pp.4, 2013, https://doi.org/10.1089/jmf.2015.3563
  7. Development of a new characteristic parameter - waveform index of finger blood volume pulse vol.21, pp.suppl1, 2016, https://doi.org/10.1080/24699322.2016.1240295
  8. Prognostic impact of alkaline phosphatase measured at time of presentation in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction vol.12, pp.2, 2013, https://doi.org/10.1371/journal.pone.0171914
  9. Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensi vol.23, pp.None, 2013, https://doi.org/10.1186/s40885-017-0074-0
  10. Aging in the Cardiovascular System: Lessons from Hutchinson-Gilford Progeria Syndrome vol.80, pp.None, 2018, https://doi.org/10.1146/annurev-physiol-021317-121454
  11. Mechanical damage characterization in human femoropopliteal arteries of different ages vol.90, pp.None, 2019, https://doi.org/10.1016/j.actbio.2019.03.053
  12. Evaluation of ultrasonography on carotid arteries and left ventricular function in patients with subclinical atherosclerosis vol.17, pp.6, 2019, https://doi.org/10.3892/etm.2019.7517
  13. Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway vol.49, pp.7, 2019, https://doi.org/10.4070/kcj.2018.0379
  14. The Concept of Early Vascular Aging vol.15, pp.5, 2013, https://doi.org/10.20996/1819-6446-2019-15-5-742-749
  15. Vascular age in patients with arterial hypertension vol.26, pp.2, 2013, https://doi.org/10.33529/angi02020209
  16. Age‐related differences in blood pressure, ultrasound‐derived arterial diameters and arterial wall stiffness parameters in horses vol.52, pp.6, 2013, https://doi.org/10.1111/evj.13263
  17. Histological and biomechanical properties of systemic arteries in young and old Warmblood horses vol.16, pp.7, 2013, https://doi.org/10.1371/journal.pone.0253730